GNFT - Pendapatan operasional sadurunge ngurangi amortisasi GENFIT

The competent French management of Genfit S.A. (GNFT) effectively manages intellectual property and transparent partnership revenues. EBITDA confirms this potential, where the 0.00 level records fresh values. Risks are associated with the dependence on a narrow niche of rare liver pathology therapies and the maintenance of a scientific advantage during clinical trials.

GNFT (GENFIT) riwayat Bathi operasional EBITDA saka 23.11.2025 nganti 06.12.2025

GENFIT (GNFT) - rincian metrik lan laporan keuangan

- rega saham lan target rega konsensus:

Bagan rega Genfit SA|GNFT - Prakiraan konsensus analis

- statistik kapitalisasi pasar:

Kapitalisasi pasar Genfit S.A.|GNFT - Rega Nyata Tumbas Perusahaan Kanthi Wutuh

- data ekuitas miturut neraca:

Aset Bersih saben Siji Saham Genfit S.A.|GNFT - Kapitalisasi Buku|Koefisien Nilai Pasar marang Nilai Buku genfit.com|GNFT - Aset Agregat Perusahaan

- indikator total utang lan likuiditas perusahaan:

Rasio Kabeh Utang marang Dana Pribadi Genfit S.A.|GNFT - Utang jangka dawa marang modal|Tanggungan utang jangka cendhak marang ekuitas Genfit SA|GNFT - Gunggung utang perusahaan|Utang-utang marang nilai buku Genfit S.A.|GNFT - Utang jangka dawa perusahaan|Tanggungan utang jangka cendhak perusahaan Genfit S.A.|Rasio likuiditas kritis genfit.com

- indikator pendapatan resik lan kelipatan nilai:

GNFT - Bathi resik|Prakiraan bathi perusahaan Genfit S.A.|GNFT - Koefisien rega marang bathi|Rasio kapitalisasi marang bathi mangsa ngarep Genfit SA|GNFT - Pangali rega marang bathi tumrap wutah|Nilai bisnis marang bathi operasional sadurunge panyusutan Genfit S.A.|GNFT - Bathi sadurunge mbayar bunga, pajak, lan amortisasi|Bathi resik saben saham sajrone patang kuartal pungkasan Genfit S.A.|GNFT - Bathi resik saben saham sajrone 12 wulan pungkasan|Owah-owahan bathi resik saben saham taun-ka-taun sajrone rolas wulan pungkasan genfit.com|GNFT - Wutah bathi ing taun lumaku|Prakiraan wutah bathi kanggo taun ngarep Genfit S.A.

Ringkesan analitik perusahaan:Genfit S.A.

This metric measures the actual cash flow from core operations before taxes and interest, excluding any accounting assumptions. The current value of 0.00 reflects the ability of Genfit S.A. (GNFT) to monetize the drug Iqirvo and license payments, which allows for an assessment of the biopharmaceutical business's resilience to market shocks and commercialization efficiency through the EBITDA_Co trend.

Pesaing Genfit S.A. (GNFT)

Arrowhead Corp - Bathi sadurunge mbayar bunga, pajak, lan amortisasi|Mirum Pharmaceuticals - Bathi operasional EBITDA|Pendapatan operasional sadurunge ngurangi amortisasi Dynavax Technologies Corp DVAX|ABUS (Arbutus Biopharma Corporation) - Bathi operasional sadurunge ngurangi amortisasi|IVA (Inventiva SA) - Bathi sadurunge mbayar bunga, pajak, lan amortisasi|GYRE (Gyre Corp) - Bathi operasional EBITDA|Bathi sadurunge bunga, pajak, lan amortisasi Assembly Corp ASMB|Bathi sadurunge mbayar bunga, pajak, lan amortisasi Galectin Therapeutics (GALT)|DRRX (durect.com) - Pendapatan sadurunge ngurangi bunga, pajak, lan amortisasi|Bathi operasional EBITDA ALGS (Aligos Therapeutics, Inc.)|Bathi operasional sadurunge potongan amortisasi BioVie Inc|Galmed Pharma - Bathi operasional EBITDA|Bathi sadurunge bunga, pajak, lan amortisasi ENDRA Corp|hepionpharma.com (HEPA) - Bathi sadurunge mbayar bunga, pajak, lan amortisasi